Adage Capital Partners’s Stemline Therapeutics, Inc. STML Stock Holding History

Adage Capital Partners’s Portfolio STML Stock Details STML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-3,068,829	Closed	-$14.9M	–	825
2020 Q1	$14.9M	Sell	3,068,829 -141,171	-4%	-$915K	0.04%	389
2019 Q4	$34.1M	Sell	3,210,000 -1,190,000	-27%	-$11.8M	0.08%	276
2019 Q3	$45.8M	Buy	4,400,000 +400,000	+10%	+$5.23M	0.11%	214
2019 Q2	$61.3M	Buy	4,000,000 +500,000	+14%	+$7.23M	0.15%	172
2019 Q1	$45M	Buy	3,500,000 +2,789,986	+393%	+$31.5M	0.11%	214
2018 Q4	$6.75M	Hold	710,014	–	–	0.02%	571
2018 Q3	$11.8M	Sell	710,014 -450,000	-39%	-$7.21M	0.03%	525
2018 Q2	$18.6M	Sell	1,160,014 -632,043	-35%	-$11.3M	0.04%	417
2018 Q1	$27.4M	Buy	1,792,057 +357,143	+25%	+$5.57M	0.06%	330
2017 Q4	$22.4M	Buy	1,434,914 +777,556	+118%	+$10.4M	0.05%	381
2017 Q3	$7.3M	Buy	+657,358	New	+$6.18M	0.02%	596

Adage Capital Partners's STML Position: Q2 2020 in Review

Adage Capital Partners sold out of Stemline Therapeutics, Inc. (STML) in Q2 2020, closing a stake of 3,068,829 shares — an estimated $14.9M sold.

Adage Capital Partners first reported a position in STML in Q3 2017 and held it in 11 quarters. The position peaked at $61.3M in Q2 2019. 0 funds tracked by Wall St. Rank hold STML as of Q2 2020.

Adage Capital Partners reported no remaining Stemline Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
Adage Capital Partners sold 3,068,829 Stemline Therapeutics, Inc. shares in Q2 2020, an estimated $14.9M.
Adage Capital Partners first reported a position in Stemline Therapeutics, Inc. in Q3 2017 and held it in 11 quarters.
Adage Capital Partners's Stemline Therapeutics, Inc. position peaked at $61.3M in Q2 2019.
0 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2020.

Based on Adage Capital Partners's 13F filing for Q2 2020, filed 14 Aug 2020.